# 19 pneumonia (n=4), Pneumonia aspiration (n=3), Urosepsis (n=2), Pneumonia

**Page range:** 59–59

```text
19 pneumonia (n=4), Pneumonia aspiration (n=3), Urosepsis (n=2), Pneumonia
cytomegaloviral, Endocarditis bacterial, Infection, Pneumocystis jirovecii pneumonia,
Lower respiratory tract infection, Urinary tract infection, Meningitis, Bronchitis and
Peritonitis (n=1 each).

The outcome where reported was resolved/resolved with sequelae for more than
half of the events (280/444), not resolved in 33/444 and resolving in 12/444 for the
non-fatal events.

The events resolved/resolved with sequelae or were resolving in half (222/444) of
the events (reported in 281/387 cases) with therapy interruption or withdrawal of
Pralsetinib. However, corrective treatment was received with broad-spectrum
antibiotics, antivirals, steroids, symptomatic management and corrective surgery in
250/ 281 cases. There was no information on the same for rest of the 31 cases.

The first dose latency ranged between 0 days to 1825 days for the majority
(417/444) of the events.
The case categories of these 387 cases are summarized below:
Category A cases:
In a total of 2 cases reporting 2 Grade 4 AEs, no alternative explanations were identified
for the events of infection. The PTs reported in these cases included Pneumocystis
jirovecii pneumonia (n=1) and Neutropenic sepsis (n=1). The first dose latencies were 65
and 1460 days and both the events resolved following pralsetinib therapy interruption
and with institution of corrective treatment. Evidence of co-existing neutropenia was
there in 1 case reporting neutropenic sepsis. The causative organisms identified in these
```